• Medical Considerations in Athletes With Stress Fractures
     

    Medical Considerations in Athletes With Stress Fractures

    Dr. Elliott Schwartz reviews the causes, epidemiology, evaluation, diagnosis and approach to individuals with stress fractures. He discusses his work with elite athletes and offers his thoughts and information about new approaches to treatment of this condition. Recorded at Northern California Institute for Bone Health, Osteoporosis Update 2015, on June […]

    Read full article

  • Biology of Fracture Nonunions 2015
     

    Biology of Fracture Nonunions 2015

    Dr. Elliott Schwartz reviews the definitions and causes of fracture nonunions, the possible underlying genetic issues, his experience treating such problems and his thoughts and information about new approaches to this vexing problem. Recorded at Northern California Institute for Bone Health, Osteoporosis Update 2015, on June 19, 2015, in Oakland, […]

    Read full article

  • What is Osteoporosis?
     

    What is Osteoporosis?

    An estimated 150 million people worldwide have osteoporosis leaving them at risk for the first-time. Due to its prevalence worldwide, osteoporosis is considered as a serious public health concern. Currently it is estimated that over 200 million people worldwide suffer from this disease1. Approximately 30% of all postmenopausal women have […]

    Read full article

  • Prescreening Tools to Determine Who Needs DXA
     

    Prescreening Tools to Determine Who Needs DXA

    Elliott N. Schwartz, MD, CCD, CPD, and Dee M. Steinberg, XT, CDT Clinical decision rules (CDRs) are designed to help physicians practice better. A number of CDRs to assist in identifying women with low bone mass have been developed since the mid 1990s, including SCORE, OST (OSTA), OSIRIS, SOFSURF, NOF, […]

    Read full article

  • Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
     

    Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.

    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. INTRODUCTION: The prevalence of both osteoporosis and renal impairment increases with age. METHODS: Using data from the Fracture Prevention Trial, the safety and efficacy of teriparatide [rhPTH(1-34)] in postmenopausal women with osteoporosis and renal impairment were explored.

    Read full article